GlassScriptPhysician profile
Thomas Eng
NPI 1790858413
$9,020.40
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,168 · 2020: $1,811 · 2021: $1,997 · 2022: $1,476 · 2023: $1,619 · 2024: $949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,568.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,552.56 | 2019-2024 | Austedo Xr, Ajovy, Austedo |
| Ucb, INC. | $1,293.10 | 2019-2024 | Briviact, Nayzilam, Rystiggo |
| Biogen, INC. | $1,139.17 | 2019-2024 | Vumerity, Tysabri, Plegridy |
| Novartis Pharmaceuticals Corporation | $745.05 | 2019-2024 | |
| Abbvie INC. | $613.17 | 2021-2024 | |
| Amgen INC. | $558.01 | 2019-2023 | Aimovig |
| Mdd US Operations, LLC | $375.33 | 2019-2024 | Gocovri, Apokyn, Apokyn |
| Lundbeck LLC | $338.34 | 2021-2024 | Vyepti, Rexulti |
| Alexion Pharmaceuticals, INC. | $297.13 | 2020-2023 | Ultomiris, Soliris |
| Amneal Pharmaceuticals LLC | $279.54 | 2021-2024 | Rytary |
| Neurelis, INC. | $264.08 | 2020-2022 | |
| Argenx US, INC. | $187.64 | 2022-2023 | Vyvgart, Vyvgart Hytrulo |
| Lilly USA, LLC | $182.95 | 2019-2024 | Emgality, Amyvid, Reyvow |
| Merz Pharmaceuticals, LLC | $164.43 | 2021-2022 | |
| Genzyme Corporation | $162.86 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $138.26 | 2024 | Rexulti |
| Emd Serono, INC. | $105.01 | 2019-2023 | Mavenclad |
| Eisai INC. | $98.27 | 2021-2022 | |
| Allergan, INC. | $90.63 | 2020-2021 | |
| Kyowa Kirin, INC. | $68.71 | 2023-2024 | Nourianz |
| Supernus Pharmaceuticals, INC. | $54.78 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $46.15 | 2019-2021 | |
| Averitas Pharma INC. | $34.95 | 2024 | Qutenza |
| Pfizer INC. | $31.18 | 2021-2024 | |
| Sk Life Science, INC. | $27.96 | 2024 | |
| Sumitomo Pharma America, INC. | $27.46 | 2024 | Aptiom |
| Medtronic, INC. | $22.36 | 2023 | Mazor X System |
| Csl Behring | $22.20 | 2020 | |
| Alfasigma USA, INC. | $21.11 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.61 | 2021 | |
| Vertical Pharmaceuticals, LLC | $14.16 | 2020 | |
| Celgene Corporation | $14.13 | 2022 | |
| Xeris Pharmaceuticals, INC. | $11.92 | 2022 | |
| Adamas Pharmaceuticals, INC. | $11.80 | 2021 | |
| Janssen Pharmaceuticals, INC | $9.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Eng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.